Rules-Based Medicine, a Q² Solutions company, was featured in a posted presented at the American Thoracic Society’s annual meeting in May 2024. The poster—Development of a Multi-biomarker Assay for Serum Proteins by the Prognostic Lung Fibrosis Consortium (PROLIFIC)—highlighted RBM’s work in developing a set of biomarkers for idiopathic pulmonary fibrosis (IPF).

Complete the form to view/download this poster.